Clinical Trials Logo

Clinical Trial Summary

The aim of this study is to correlate the autoantibody against oxidized LDL with disease activity and cardiovascular affection in patients with SLE.


Clinical Trial Description

Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disease affecting mainly women of fertile age. It is characterized by hyperactivity of B-cells and by overproduction of autoantibodies without organ specificity, many of which contribute to the formation of immunocomplexes. Their deposition in tissues and blood vessels results in inflammatory organ impairment (Khairy et al., 2017). As for the laboratory findings in SLE, production of autoantibodies without organ specificity aimed at nuclear, cytoplasmic, and surface antigens of the patient's body is typical. The most common SLE manifestations include involvement of skin, joints, cardiovascular system, lungs, renal glomeruli, central nervous system or hematopoiesis. SLE can result in failure of the involved organs, severe forms of SLE thus bein gassociated with significant mortality (Pashnina et al., 2021). Cardiovascular involvement is associated with increased morbidity and mortality of SLE patients. The most common SLE-related cardiovascular events are myocardial infarctions (MIs), cerebrovascular events, thromboembolic events (TEs), heart failure, and sudden death. Cardiovascular events are proportionally higher in SLE compared to general populations of comparable age and sex (Ramirez et al., 2020). The pathogenic mechanisms of different cardiac diseases in SLE are still incompletely understood. Traditional risk factors for Cardiovascular affection, such as older age, high blood pressure (BP), high cholesterol and triglycerides, smoking, obesity, diabetes mellitus, and - last but not least - SLE therapy all play a critical role. These factors alone cannot adequately explain the increased incidence of cardiovascular disease commonly reported in patients with SLE. Metabolic syndrome was considered a remarkable risk factor for the development of subclinical atherosclerosis and increased carotid intima-media thickness The non-traditional biomarkers included both leptin and homocysteine, where leptin acts on the immune system as aproinflammatory cytokine. It promotes the proliferation and activation of T lymphocytes and induces production of Th1 cytokines. Homocysteinelevels have been identified as a predictor of atherosclerosis in patients with SLE, in whom high levels may be predictive levels of coronary calcification, platelet progression and increased IMT (Khairy et al., 2017). Specific antibodies cause oxidation of low density lipoprotein (LDL) particles, thus accentuating their atherogenic effect, or exert a negative influence on the character of physiologically protective High density lipoprotein (HDL) particles. Endothelial dysfunction within the vascular system ensues, increasing its vulnerability, affinity to lipoproteins and activity of enzymes accelerating the development of atherosclerosis (Li et al., 2020). LDLs are transported into artery walls, where they become trapped and bound in the extracellular matrix of the subendothelial space. These trapped LDLs are then seeded with reactive oxygen species produced by nearby artery wall cells, resulting in the formation of proinflammatory Oxidized LDL (OxLDL). oxLDL plays an important role in atherogenesisand may contribute to the immune activation and inflammation present in the atherosclerotic lesions, because it has chemotactic, immune-stimulatory, and toxic properties and is taken up by macrophages and other cells in the atherosclerotic plaque, which develop into foam cells. Epitopes characteristic of oxidized LDL can be found in atherosclerotic lesions by immunocytochemical techniques and atherosclerotic lesions contain immunoglobulins that recognize oxLDL (Ammar et al., 2021). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05479071
Study type Observational [Patient Registry]
Source Assiut University
Contact Haddeel Sayed ahmed, Dr
Phone 0020109427161
Email Drhaddeel@gmail.com
Status Not yet recruiting
Phase
Start date September 1, 2022
Completion date October 1, 2023

See also
  Status Clinical Trial Phase
Completed NCT02240888 - Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response N/A
Active, not recruiting NCT05748925 - Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients Phase 4
Not yet recruiting NCT04517240 - A Study on Protein Losing Enteropathy In Systemic Lupus Erythematosus
Completed NCT00710021 - Vitamin D3 in Systemic Lupus Erythematosus Phase 2
Terminated NCT01946880 - Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE) Phase 2
Recruiting NCT06445127 - Evaluation of Patients With Lupus Nephritis Using Kidney MRI (Magnetic Resonance Imaging) N/A
Active, not recruiting NCT04018222 - Translation of a Diagnostic Test for Lupus Flare Prediction From Bench to Clinic
Completed NCT03240536 - Choosing Tests Wisely in Rheumatology N/A
Completed NCT04368299 - Telemedicine for Follow-up of Systemic Lupus Erythematosus N/A
Active, not recruiting NCT04037293 - Premature Atherosclerosis in Systemic Lupus Erythematosus
Not yet recruiting NCT04234633 - Effect of Gender on Clinical Presentation of SLE ِAt Assiut University Hospitals
Completed NCT01207297 - Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis Phase 1
Terminated NCT00152555 - Physical Therapy for Systemic Lupus Erythematosus (SLE) N/A
Recruiting NCT05822219 - Vaccine Hesitancy in Black/African Americans With Rheumatic Diseases N/A
Completed NCT04806113 - COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases Phase 3
Recruiting NCT05966480 - Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus Phase 2
Completed NCT03155477 - Effect Of Curcuma Xanthorrhiza and Vitamin D3 Supplementation in SLE Patients With Hypovitamin D N/A
Recruiting NCT05342285 - Flow Mediated Dilation in Association With Hyperuricemia
Not yet recruiting NCT03984227 - New Signaling Pathway Targeting Systemic Lupus Erythematosus
Enrolling by invitation NCT03144063 - Improving the Assessment of SLE Disease Activity N/A